Skip to content

Study · Non-randomized trial · n = 28 · 1985

11 results

Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle.

Monroe SE, Henzl MR, Martin MC, Schriock E, Lewis V, Nerenberg C, Jaffe RB

Fertility and sterility1 Mar 1985Cited by 16 (Europe PMC)

PMID3156770 (opens in a new tab)DOI10.1016/s0015-0282(16)48432-3 (opens in a new tab)PepBankPUB-03156770
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In normal women, nafarelin entered circulation rapidly after injection.

    In plain wordsIn normal women, nafarelin entered circulation rapidly after injection.

    Peptide
    Nafarelin
    Outcome
    Not applicableEntry into circulation
    Study

    n = 28

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Nafarelin entered the circulation rapidly after injection.
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  2. 02HumanNon-randomized trialPharmacokinetics

    In normal women, nafarelin peak concentrations occurred within 1 hour.

    In plain wordsIn normal women, nafarelin peak concentrations occurred within 1 hour.

    Peptide
    Nafarelin
    Outcome
    Not applicableTime to peak plasma concentration
    Study

    n = 28

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Time to peak plasma concentration
    ≤ 1 hour
    after subcutaneous injection

    Source sentences

    Summary
    Peak concentrations were observed within 1 hour, and the plasma half-life was 4 to 5 hours.
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  3. 03HumanNon-randomized trialPharmacokinetics

    In normal women, nafarelin plasma half-life was 4 to 5 hours.

    In plain wordsIn normal women, nafarelin plasma half-life was 4 to 5 hours.

    Peptide
    Nafarelin
    Outcome
    Not applicablePlasma half-life
    Study

    n = 28

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Plasma half-life
    4 to 5 hours
    after subcutaneous injection

    Source sentences

    Summary
    Peak concentrations were observed within 1 hour, and the plasma half-life was 4 to 5 hours.
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  4. 04HumanNon-randomized trialActivity measurement

    In normal women, LH peaked 3 to 4 hours after nafarelin administration.

    In plain wordsIn normal women, LH peaked 3 to 4 hours after nafarelin administration.

    Peptide
    Nafarelin
    Outcome
    Not applicableTime to maximal LH concentration
    Study

    n = 28

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Time to maximal LH concentration
    3 to 4 hours
    after nafarelin administration

    Source sentences

    Summary
    Maximal concentrations of luteinizing hormone and follicle-stimulating hormone were reached 3 to 4 hours after nafarelin administration.
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  5. 05HumanNon-randomized trialActivity measurement

    In normal women, FSH peaked 3 to 4 hours after nafarelin administration.

    In plain wordsIn normal women, FSH peaked 3 to 4 hours after nafarelin administration.

    Peptide
    Nafarelin
    Outcome
    Not applicableTime to maximal FSH concentration
    Study

    n = 28

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Time to maximal FSH concentration
    3 to 4 hours
    after nafarelin administration

    Source sentences

    Summary
    Maximal concentrations of luteinizing hormone and follicle-stimulating hormone were reached 3 to 4 hours after nafarelin administration.
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  6. 06HumanNon-randomized trialActivity measurement

    In normal women, gonadotropin responses to nafarelin depended on dose, without a reported direction.

    In plain wordsIn normal women, gonadotropin responses to nafarelin depended on dose.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedDose dependence of gonadotropin response
    Study

    n = 28

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The magnitude of the gonadotropin responses depended both on the phase of the menstrual cycle (smallest responses during the early follicular phase) and the dose of nafarelin.
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  7. 07HumanNon-randomized trialActivity measurement

    In normal women, early follicular nafarelin delayed ovulation by 4.6 +/- 1.7 days.

    In plain wordsIn normal women, early follicular nafarelin delayed ovulation by an average of 4.6 days.

    Peptide
    Nafarelin
    Outcome
    IncreaseOvulation delay
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Ovulation delay, mean
    4.6 days
    early follicular phase administration
    Ovulation delay, SD
    1.7 days
    early follicular phase administration

    Source sentences

    Summary
    Nafarelin administration during the early follicular phase delayed ovulation by 4.6 +/- 1.7 (standard deviation) days and prolonged the duration of the menstrual cycle from a pretreatment length of 29.2 +/- 2.1 days to 33.4 +/- 4.0 days (P less than 0.001).
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  8. 08HumanNon-randomized trialActivity measurement

    In normal women, early follicular nafarelin prolonged cycle length from 29.2 +/- 2.1 to 33.4 +/- 4.0 days.

    In plain wordsIn normal women, early follicular nafarelin prolonged cycle length compared with pretreatment.

    Peptide
    Nafarelin
    Outcome
    IncreaseEarly follicular cycle length
    Study

    n: not reported in source

    Comparator
    pretreatment cycle length
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Cycle length, mean
    29.2 days
    pretreatment
    Cycle length, SD
    2.1 days
    pretreatment
    Cycle length, mean
    33.4 days
    early follicular nafarelin
    Cycle length, SD
    4 days
    early follicular nafarelin

    Source sentences

    Summary
    Nafarelin administration during the early follicular phase delayed ovulation by 4.6 +/- 1.7 (standard deviation) days and prolonged the duration of the menstrual cycle from a pretreatment length of 29.2 +/- 2.1 days to 33.4 +/- 4.0 days (P less than 0.001).
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  9. 09HumanNon-randomized trialActivity measurement

    In normal women, nafarelin shortly before or after ovulation did not consistently alter cycle length.

    In plain wordsIn normal women, nafarelin shortly before or after ovulation did not consistently alter cycle length.

    Peptide
    Nafarelin
    Outcome
    MixedPeriovulatory cycle length
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    When nafarelin was administered shortly before or after ovulation, cycle length was not altered consistently.
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  10. 10HumanNon-randomized trialActivity measurement

    In normal women, nafarelin given 5 to 10 days after ovulation shortened the luteal phase.

    In plain wordsIn normal women, nafarelin given 5 to 10 days after ovulation shortened the luteal phase.

    Peptide
    Nafarelin
    Outcome
    DecreaseLuteal phase length
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Administration 5 to 10 days after ovulation resulted in a truncated luteal phase.
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.
  11. 11HumanObservational studyActivity measurement

    In normal women given nafarelin, gonadotropin responses were smallest during the early follicular phase.

    In plain wordsIn normal women given nafarelin, the early follicular phase was linked to smaller gonadotropin responses than other phases.

    Peptide
    Nafarelin
    Outcome
    DecreaseGonadotropin response by cycle phase
    Study

    n: not reported in source

    Comparator
    other menstrual cycle phases
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    single dose of 1, 5, 20 or 100 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The magnitude of the gonadotropin responses depended both on the phase of the menstrual cycle (smallest responses during the early follicular phase) and the dose of nafarelin.
    1 context sentence
    Summary · context
    Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.